Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Launched by PFIZER · Aug 24, 2015
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
This is a multi-center chart review registry on mRCC patients treated with axitinib. Primary objective is the dose adjustment. Secondary objectives are safety profile, objective response rate and progression free survival. Efficacy assessment will be based on investigators' judgment. Patients treated with 1st dose of axitinib between May 7, 2013 and June 30, 2015 will be enrolled. The follow-up time is 12 months. Prior therapies should include sunitinib or interferon alpha.
Gender
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed as advanced RCC by histology or cytology
- • Patients using axitinib as therapy after failure of sunitinib or cytokine
- • Patients received axitinib treatment and follow up in the health care center participating present registry
- • Patients agree to participate and signed inform consent or IRB waiving of signed informed consent document is available
- Exclusion Criteria:
- • Patients with first dose of axitinib earlier than 7th May 2013
- • Patients with first dose of axitinib later than 30th June 2015.
- • Patients participating in clinical research involving axitinib
- • Patients with hypersensitivity to axitinib or to any other component of axitinib
- • Patients under 18-year of age
- • Pregnant women.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials